Ablynx, Boehringer Ingelheim Ink Nanobody Therapeutics Agreement

Belgian drugmaker Ablynx and German pharmaceutical company Boehringer Ingelheim announced an alliance to discover, develop and commercialize approximately 10 nanobody therapeutics.

Ablynx said it expects to receive payments of roughly $102.5 million during the research term of the collaboration. The company added that it will receive development milestone payments for each nanobody which is developed of a maximum of $170.8 million, as well as undisclosed royalties.

Ablynx and Boehringer Ingelheim said they will collaborate jointly in the discovery of nanobodies in multiple therapeutic areas including immunology, oncology and respiratory.

Boehringer Ingelheim will be exclusively responsible for the development, manufacture and commercialization of any products resulting from the collaboration. Ablynx said it will have certain co-promotion rights in Europe.